Citations

Clear

3030 citation(s) found for "Susan, M".

Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk
Li, Yafang , Xiao, Xiangjun , Cheng, Chao , McKay, James , Lam, Stephen , Tardón, Adonina , Chen, Chu, Bojesen, Stig E. , Landi, Maria Teresa , Risch, Angela , Wichmann, H‐Erich, Rennert, Gad , Goodman, Gary E. , Field, John K. , Davies, Michael P.A. , Shete, Sanjay , Melander, Olle , Brunnström, Hans , Hung, Rayjean J, Andrew, Angeline S. , Shen, Hongbing , Zienolddiny, Shan, Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan P. , Purrington, Kristen S. , Bailey‐Wilson, Joan E. , Mandal, Diptasri , Willey, James C. , Gaba, Colette , Brennan, Paul , Hung, Rayjean J. , Rennert, Gad , Cheng, Chao , Wilson, Richard K , Hung, Rayjean J , Field, John K , Tardón, Adonina , Davies, Michael P A , Bojesen, Stig E , Risch, Angela , Grankvist, Kjell , Purrington, Kristen S , Willey, James C , Shen, Hongbing , Li, Jianrong , Byun, Jinyoung , Bossé, Yohan , Albanes, Demetrius , Johansson, Mattias , Bickeböller, Heike , Christiani, David C. , Arnold, Susanne M. , Marchand, Loı̈c Le , Liu, Geoffrey , Kiemeney, Lambertus A. , Sun, Ryan , Teare, M. Dawn , Hong, Yun‐Chul , Lazarus, Philip J. , Schabath, Matthew B. , Yang, Ping , Liu, Yanhong , Han, Younghun , Pinney, Susan M. , Amos, Christopher I.

Mayo Clinic

Human Molecular Genetics | February 1, 2022 | Volume: 31 | Issue: 16 | Pages: 2831-2843

10.1093/hmg/ddac030 | PMID 35138370 Get It

Abstract Differences by sex in lung cancer incidence and mortality have been reported which cannot be fully explained by sex differences in smoking behavior, implying existence of genetic and molecular basis for sex disparity in lung cancer development. However, the information about sex dimorphism in lung cancer risk is quite limited despite the great success in lung cancer association studies. By adopting a stringent two-stage analysis strategy, we performed a genome-wide gene–sex interaction analysis using genotypes from a lung cancer cohort including ~ 47 000 individuals with European ancestry. Three low-frequency variants (minor allele frequency < 0.05), rs17662871 [odds ratio (OR) = 0.71, P = 4.29×10−8); rs79942605 (OR = 2.17, P = 2.81×10−8) and rs208908 (OR = 0.70, P = 4.54×10−8) were identified with different risk effect of lung cancer between men and women. Further expression quantitative trait loci and functional annotation analysis suggested rs208908 affects lung cancer risk through differential regulation of Coxsackie virus and adenovirus receptor gene expression in lung tissues between men and women. Our study is one of the first studies to provide novel insights about the genetic and molecular basis for sex disparity in lung cancer development.
Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease
Barthélemy, Nicolas R. , Goate, Alison , Hassenstab, Jason , Fagan, Anne M. , Xiong, Chengjie , Cruchaga, Carlos , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Masters, Colin L. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Chhatwal, Jasmeer P. , Fitzpatrick, Colleen , Bodge, Courtney, Cruz, Chrismary De La, Mejia, Arlene, Neimeyer, Katie, Gardener, Samantha L. , Taddei, Kevin , Ping, Lingyan, Seyfried, Nick , Gräber‐Sultan, Susanne, Häsler, Lisa M., Käser, Stephan, Kuder-Buletta, Elke, Preische, Oliver, Diffenbacher, Anna, Igor, Yakushev, Levin, Johannes, Vöglein, Jonathan , Obermüller, Ulricke, Esposito, Bianca, Goate, Alison, Buck, Jill , Farlow, Marty, Chrem, Patricio, Egido, Noelia , Haass, Christian , Nuscher, Brigitte , Day, Gregory S. , Graham, Morgan, Stephens, Sochenda, Bechara, Jacob , Araki, Aki, Ishii, Kenji , Senda, Michio , Ihara, Ryoko , Nagamatsu, Akemi, Fox, Nick C. , Mummery, Cath, Goldberg, Sarah B. , Ikonomović, Snežana, Mountz, James M. , Nadkarni, Neelesh K. , Patira, Riddhi , Smith, Lori, Snitz, Beth E. , Thompson, Sarah , Weamer, Elise A., Mason, Neal Scott, Chui, Helena, Ringman, John M. , Adams, Sarah , Brandon, Susan E. , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chua, Jasmin, Cruchaga, Carlos, Denner, Darcy, Dincer, Aylin , Donahue, Tamara, Feldman, Becca , Franklin, Erin , Friedrichsen, Nelly, Gonzalez, Alyssa, Gray, Julia, Gremminger, Emily, Groves, Alex, Hassenstab, Jason, Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Jerome, Gina, Keefe, Sarah , Koudelis, Deb, Martinez, Rita, Mawuenyega, Kwasi G., McCullough, Austin , McDade, Eric, Norton, Joanne, Perrin, Richard J. , Shady, Kristine, Sigurdson, Wendy, Xu, Jinbin , Cruchaga, Carlos , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Lim, Yen Ying , Maruff, Paul , Sato, Chihiro , Benzinger, Tammie L.S. , Xiong, Chengjie , Schofield, Peter R. , McDade, Eric , Network, Dominantly Inherited Alzheimer, Fitzpatrick, Colleen, Goldman, Jill , Noble, James M. , Martins, Ralph N. , Sohrabi, Hamid R. , Carter, Kathleen, Duong, Duc M , Johnson, Erik C. B. , Levey, Allan I. , Ping, Lingyan, Hofmann, Anna, Jucker, Mathias , Levin, Johannes, Goate, Alison, Renton, Alan , Brosch, Jared R. , Buck, Jill, Ghetti, Bernardino , Allegri, Ricardo , Morenas‐Rodríguez, Estrella , Jack, Clifford R. , Brooks, William S. , Ikeuchi, Takeshi , Kasuga, Kensaku , Fujii, Hisako , Shimada, Hiroyuki , Niimi, Yoshiki , Douglas, Jane, Grilo, Miguel, O’Connor, Antoinette , Koeppe, Robert A. , Berman, Sarah , Klunk, William E. , López, Oscar L. , Brandon, Susan, Cruchaga, Carlos, Feldman, Becca, Flores, Shaney , Gordon, Brian A. , Hassenstab, Jason, Holtzman, David M. , Karch, Celeste M. , Li, Yan , Marsh, Jacob, McDade, Eric, Smith, Jennifer A. , Wang, Peter , Wang, Qing , Xu, Xiong

Mayo Clinic

JAMA Neurology | January 31, 2022 | Volume: 79 | Issue: 3 | Pages: 261

10.1001/jamaneurol.2021.5181 | PMID 35099506 Get It

Effects of patient-reported outcome assessment order
Novotny, Paul J. , Dueck, Amylou C. , Satele, Daniel , Frost, Marlene H., Beebe, Timothy J. , Yost, Kathleen J. , Lee, Minji K. , Yount, Susan , Cella, David , Mendoza, Tito R. , Cleeland, Charles S. , Blinder, Victoria , Basch, Ethan , Sloan, Jeff A. , Eton, David T. , Dueck, A. C. , Mendoza, Tito , Basch, Ethan

Mayo Clinic

Clinical Trials | January 28, 2022 | Volume: 19 | Issue: 3 | Pages: 307-315

10.1177/17407745211073788 | PMID 35088616 Get It

Background In clinical trials and clinical practice, patient-reported outcomes are almost always assessed using multiple patient-reported outcome measures at the same time. This raises concerns about whether patient responses are affected by the order in which the patient-reported outcome measures are administered. Methods This questionnaire-based study of order effects included adult cancer patients from five cancer centers. Patients were randomly assigned to complete questionnaires via paper booklets, interactive voice response system, or tablet web survey. Linear Analogue Self-Assessment, Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, and Patient-Reported Outcomes Measurement Information System assessment tools were each used to measure general health, physical function, social function, emotional distress/anxiety, emotional distress/depression, fatigue, sleep, and pain. The order in which the three tools, and domains within tools, were presented to patients was randomized. Rates of missing data, scale scores, and Cronbach’s alpha coefficients were compared by the order in which they were assessed. Analyses included Cochran–Armitage trend tests and mixed models adjusted for performance score, age, sex, cancer type, and curative intent. Results A total of 1830 patients provided baseline patient-reported outcome assessments. There were no significant trends in rates of missing values by whether a scale was assessed earlier or later. The largest order effect for scale scores was due to a large mean score at one assessment time point. The largest difference in Cronbach’s alpha between the versions for the Patient-Reported Outcomes Measurement Information System scales was 0.106. Conclusion The well-being of a cancer patient has many different aspects such as pain, fatigue, depression, and anxiety. These are assessed using a variety of surveys often collected at the same time. This study shows that the order in which the different aspects are collected from the patient is not important.
Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.
Mehdi, Maahum , Annunzio, Kaitlin , Taylor, Bradley , Shreenivas, Aditya , Chakrabarti, Sakti , Thomas, James P. , Christians, Kathleen K. , Evans, Douglas B. , Hall, William A. , George, Ben , Chakrabarti, Sakti , Taylor, Bradley , Szabó, Anikó , Tsai, Susan , Clarke, Callisia N. , Erickson, Bradley A. , Thapa, Bicky , Ahmed, Gulrayz , Kamgar, Mandana

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 596-596

10.1200/jco.2022.40.4_suppl.596 Get It

596 Background: Genomic alterations (GA) that drive cancer development and predict therapeutic response remain elusive in patients (pts) with KRAS WT PDAC. We interrogated our institutional database to identify actionable GAs in pts with metastatic, KRAS WT PDAC and analyzed the therapeutic impact of matched TT. Methods: We reviewed electronic medical records of KRAS WT PDAC pts (n=24) who underwent comprehensive genomic profiling (CGP) utilizing Foundation One CDx (25.0%) or Tempus (75.0%) between 2015-2021. Duration of response (DOR) was calculated from date of treatment (Tx) initiation to Tx discontinuation. Overall survival (OS) was measured from the date of the diagnosis (Dx) of advanced disease (AD) to death or last follow-up. OS was estimated using the Kaplan-Meier method, with at-risk periods left-truncated at the time of CGP. The effect of covariates on survival was evaluated using Cox proportional hazards regression. Results: Of the 24 KRAS WT pts, 14 (58%) had AD: 8 (57%) pts had metastatic disease at or shortly after Dx, 6 (43%) pts developed metachronous recurrence. Median age at Dx for pts with AD was 65, and 57% were female. Seven of 14 pts with AD (50%) had highly actionable GA (HAGA), (Table). Pts with HAGA demonstrated durable responses to TT (Table) with manageable toxicities. Pts with HAGA had a median OS of 28 mo compared to 5.9 mo for those without (Hazard Ratio = 0.47, p = 0.33). Conclusions: The sustained therapeutic benefit noted with TT matched to HAGA in pts with KRAS WT PDAC underscores the need for systematic interrogation of the somatic genome in PDAC pts. Optimal sequencing of cytotoxic therapy with TT and its impact on modulating clonal selection pressure in pts with KRAS WT PDAC merits prospective evaluation.[Table: see text]
Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.
Shreenivas, Aditya , George, Ben , Puckett, Lindsay , Chakrabarti, Sakti , Straza, Michael , Hall, William A. , Loy, Veronica , Rilling, William S., Hong, Johnny C. , Gamblin, T. Clark , Smolock, Amanda R. , Christians, Kathleen K. , Dougherty, Kali, Durazo, Francisco , Chakrabarti, Sakti , Thomas, James P. , Awan, Musaddiq J. , Kamgar, Mandana , Tsai, Susan , Danziger, Natalie , Ross, Jeffrey S.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 474-474

10.1200/jco.2022.40.4_suppl.474 Get It

474 Background: FLO is a rare variant of liver cancer that disproportionately affects young adults and is frequently progressive and fatal as it is often detected in a clinically advanced stage. It is seldom associated with cirrhosis of liver, viral hepatitis or other risk factors associated with conventional HCC. Treatment options are largely limited to surgical resection, and there is dearth of effective targeted therapies for FLO. Methods: Comprehensive genomic profiling (CGP) was performed using the Foundation Medicine Inc. (FMI) data base on 63 FLO and 1,793 HCC clinically advanced cases between 6/2013-12/2020 using a hybrid capture-based assay of up to 324 genes a to detect genomic alterations (GA), tumor mutational burden (TMB) and microsatellite instability (MSI). PD-L1 expression in tumor cells (Dako 22C3) was measured by IHC and scored using the tumor proportion score (TPS) method. Results: The FLO patients (pts) were significantly younger than HCC pts (median age 20 vs. 64, respectively) and the male preponderance was similar. The HCC group featured significantly more GA/tumor than FLO group (3.74 vs 1.31 p<.0001). In the currently untargetable GA group, CTNNB1, TERT and TP53 GA were significantly more frequent in HCC than FLO. GA in potentially targetable genes were extremely uncommon in both FLO and HCC with HCC featuring slightly more MTOR pathway targets ( PTEN, TSC2, NF1). GA in DNA damage and repair (DDR) pathway including BRCA2 were infrequent in both groups. GA in targetable kinases including EGFR, ERBB2, ALK, RET and PIK3CA were extremely uncommon in both groups. GA associated with intrahepatic cholangiocarcinoma (IDH1, FGFR2) were extremely uncommon in these tumors. Although the mean TMB was significantly higher in HCC than FLO, overall TMB was low with very few cases having TMB > 10 mutations/Mb. PD-L1 expression was relatively low in both groups. GA in genes associated with immune checkpoint inhibitors (ICPI) drug response like PBRM1, CD274, MDM2, STK11 were rarely identified in both groups. Additional details are illustrated in the table. Conclusions: Comparison of CGP of FLO with HCC illustrates the multifarious nature of these cancers. In HCC, there is a high prevalence of GA in TERT, CTNNB1 and TP53. CGP identified certain targetable GA in the MTOR and DDR pathways and TMB was higher in HCC. These findings warrant further evaluation of clinically advanced FLO and HCC pts by CGP to identify possible targetable genomic pathways. [Table: see text]
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
Tine, Brian Andrew Van, Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Pelham, Joshua, Anand, Banmeet S. , Strack, Thomas , Sandri, Andrés Machado, Hubbard, Joleen M. , Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Lerner, Susan A. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 297-297

10.1200/jco.2022.40.4_suppl.297 Get It

297 Background: MT-5111 is a 55 kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may demonstrate efficacy in patients (pts) resistant to other HER2-targeting agents, as its mechanism of action induces direct cell kill via enzymatic and permanent ribosome destruction and does not rely on inhibition of kinase signaling or cytoskeletal or DNA damage. Methods: This is a phase 1 study in adult pts with advanced HER2+ solid tumors. The dose-escalation portion (modified 3+3 design) enrolls pts into sequential cohorts followed by expansion cohorts for HER2+ breast cancer (BC), gastric or gastroesophageal junction adenocarcinoma (GEA), and other HER2+ tumors. MT-5111 is dosed weekly IV over 30 min in each 21-day treatment (tx) cycle until disease progression, unacceptable toxicity, death, or withdrawn consent. Results: As of Sep 2021 (contains preliminary data), 24 pts (mean age 64 yrs) were treated, 13 (54%) of whom had gastrointestinal (GI) tumors (6 biliary, 3 GEA, 2 pancreatic, 2 colo/rectal) (Table). Pts with GI tumors had a median of 3 prior systemic tx and 1 prior HER2-targeting tx. No Grade (G) 4/5 tx-emergent adverse events (AEs) occurred. Tx-related AEs occurred in 13 (54%) pts, most commonly fatigue (n=7, 29%). One pt with biliary cancer and concurrent lymphangitic carcinomatosis and H. influenzae infection (4.5 µg/kg) had a possibly related G3 serious AE (SAE) of dyspnea, which resolved 9 days later. Another related SAE occurred in a pt with GEA (6.75 µg/kg) who had a G1 transient troponin increase that resolved during hospitalization, with no clinical symptoms or ECG/ECHO changes; the pt withdrew from study before further dosing. All other related AEs were ≤G2. No other clinically significant changes in cardiac biomarkers (troponin, ECG, LVEF) or cases of capillary leak syndrome occurred. Two pts (3 and 4.5 µg/kg) had reversible G2 infusion-related reactions. Best response to date has been stable disease. AUClast data matched PK simulations based on non-human primate studies. Cmax data at 10 µg/kg indicate that current in-pt exposure was between IC50 values of high and medium HER2-expressing cell lines (approx 10-89 ng/mL). Thus, at least 10 µg/kg may be required to achieve effective exposure. No dose-limiting toxicities have been observed. The 10 µg/kg cohort is now accruing. Following this cohort, an expansion cohort for pts with BC will open. Conclusions: MT-5111 was well tolerated with no clinically significant immuno/cardiotoxicity. Dose escalation is ongoing and is nearing levels expected to be required for efficacious exposure. Clinical trial information: NCT04029922. [Table: see text]
The Alliance AMBUSH Trial: Rationale and Design
Mahajan, Anita , Peñas-Prado, Marta , Aldape, Kenneth, Hu, Leland , Basso, Michael R. , Nahed, Brian V. , Stott, Shannon L. , Geyer, Susan M. , Shih, Helen A. , Ligon, Keith L , Loughan, Ashlee R. , Leeper, Heather , Giannini, Caterina , Galanis, Evanthia

Mayo Clinic

Cancers | January 14, 2022 | Volume: 14 | Issue: 2 | Pages: 414

10.3390/cancers14020414 | PMID 35053576 Get It

Unlike medulloblastoma (MB) in children, robust prospective trials have not taken place for older patients due to the low incidence of MB in adults and adolescent and young adults (AYA). Current MB treatment paradigms for older patients have been extrapolated from the pediatric experience even though questions exist about the applicability of these approaches. Clinical and molecular classification of MB now provides better prognostication and is being incorporated in pediatric therapeutic trials. It has been established that genomic alterations leading to activation of the sonic hedgehog (SHH) pathway occur in approximately 60% of MB in patients over the age of 16 years. Within this cohort, protein patched homolog (PTCH) and smoothened (SMO) mutations are commonly found. Among patients whose tumors harbor the SHH molecular signature, it is estimated that over 80% of patients could respond to SHH pathway inhibitors. Given the advances in the understanding of molecular subgroups and the lack of robust clinical data for adult/AYA MB, the Alliance for Clinical Trial in Oncology group developed the AMBUSH trial: Comprehensive Management of AYA and Adult Patients with Medulloblastoma or Pineal Embryonal Tumors with a Randomized Placebo Controlled Phase II Focusing on Sonic Hedgehog Pathway Inhibition in SHH Subgroup Patients (Adult & Adolescent MedulloBlastoma Using Sonic Hedgehog Trial). This trial will enroll patients 18 years of age or older with MB (any molecular subgroup and risk stratification) or pineal embryonal tumor. Patients will be assigned to one of three cohorts: (1) average risk non-SHH-MB, (2) average risk SHH-MB, and (3) high risk MB or pineal embryonal tumors. All patients will receive protocol-directed comprehensive treatment with radiation therapy and chemotherapy. Patients with SHH-MB in cohort 1 will be randomized to a smoothened inhibitor or placebo as maintenance therapy for one year.
Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis
Perou, Charles M. , Hinoue4, Toshinori, Wheeler, Gregory , Kelly, Benjamin , Garrido-Castro, Ana C. , Cubas, Aguirre De, Rajkovic, Andrei, Karaesmen, Ezgi , Fan, Cheng, Creighton, Chad J. , Leraas, Kristen , Burns, Robyn, Coppens, Sara E. , Wheless, Amy, Rezk, Salma, Garrett, Amy, Foy, Kelly K. , Park, Ben, Krop, Ian E. , Anders, Carey K. , Rimawi, Mothaffar F. , Nanda, Rita , Storniolo, Anna Maria , Chandran, Uma , Davis, Michael J. , Ropelewski, Alexander J. , Liu, Minetta C. , Richardson, Andrea L. , Symmans, W. Fraser , Davidson, Nancy E. , King, Tari A. , Perou, Charles M , Rimawi, Mothaffar , Symmans, W Fraser , García‐Recio, Susana , Hinoue4, Toshinori, Pascual, Tomás , Xia, Youli , McClure, Marni B. , Smith, Markia A. , Fan, Cheng, Bowen, Jay , Parker, Joel S. , Shen, Hui , Gastier‐Foster, Julie M. , Lin, Nancy U. , Isaacs, Claudine , Marcom, Paul Kelly , Couch, Fergus J. , Silverstein, Jonathan C. , Hilsenbeck, Susan Galloway , Norton, Larry , Wolff, Antonio C. , Carey, Lisa A. , Lee, Adrian V. , Balko, Justin M. , Hoadley, Katherine A. , Laird, Peter W. , Mardis, Elaine R.

Mayo Clinic

No container title available | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1221704/v1 Get It

Abstract Patients with metastatic breast cancer (MBC) typically have short survival times and their successful treatment represents one of most challenging aspects of patient care. This poor prognostic behavior is in part due to molecular features including increased tumor cell clonal heterogeneity, multiple drug resistance mechanisms, and alterations of the tumor microenvironment. The AURORA US Metastasis Project was established with the goal to identify molecular features specifically associated with metastasis. We therefore collected and molecularly characterized specimens from 55 metastatic breast cancer (BC) patients representing 51 primary cancers and 102 metastases. The 153 unique tumors were assayed using RNAseq, tumor/germline DNA exomes and low pass whole genome sequencing, and global DNA methylation microarrays. We found intrinsic molecular subtype differences between primary tumors and their matched metastases to be rare in triple negative breast cancer (TNBC)/Basal-like subtype tumors. Conversely, tumor subtype changes were relatively frequent in estrogen receptor positive (ER+) cancers where ~30% of Luminal A cases switched to Luminal B or HER2-enriched (HER2E) subtypes. Clonal evolution studies identified changes in expression subtype coincident with DNA clonality shifts, especially involving HER2 amplification and/or the HER2E expression subtype. We further found evidence for ER-mediated downregulation of genes involved in cell-cell adhesion in metastases. Microenvironment differences varied according to tumor subtype where ER+/Luminal metastases had lower fibroblast and endothelial cell content, while TNBC/Basal-like metastases showed a dramatic decrease in B cells and T cells. In 17% of metastatic tumors, we identified DNA hypermethylation and/or focal DNA deletions near HLA-A that were associated with its’ significantly reduced expression, and with lower immune cell infiltrates. We also identified low immune cell features in brain and liver metastases when compared to other metastatic sites, even within the same patient. These findings have direct implications for the treatment of metastatic breast cancer patients with immune- and HER2-targeting therapies and suggest potential novel therapeutic avenues for the improvement of outcomes for some patients with MBC.
Association of Accuracy, Conclusions, and Reporting Completeness With Acceptance by Radiology Conferences and Journals
Frank, Robert , Hallgrimson, Zachary , Korevaar, Daniël A. , Cohen, Jérémie F. , McInnes, Matthew D. F. , Treanor, Lee , McGrath, Trevor A. , Sharifabadi, Anahita Dehmoobad , Atyani, Almohannad , Kazi, Sakib , Choo‐Foo, Jade , Asraoui, Nabil, Ha, Winston , Prager, Ross , Rooprai, Paul, Pozdnyakov, Alex , John, Susan , Osman, Heba, Islam, Nayaar , Li, Nicole , Gauthier, Isabelle , Absi, Marissa , Kraaijpoel, Noémie , Ebrahimzadeh, Sanam , Stoker, Jaap , Frank, Robert A , McInnes, Matthew D F , McGrath, Trevor A , Alabousi, Mostafa , Stoker, Jaap , Fabiano, Nicholas , Bossuyt, Patrick M. , Leeflang, Mariska , Moher, David , Salameh, Jean‐Paul , Port, John D. , Klein, Jeffrey S. , Schweitzer, Mark

Mayo Clinic

Journal of Magnetic Resonance Imaging | January 8, 2022 | Volume: 56 | Issue: 2 | Pages: 380-390

10.1002/jmri.28046 | PMID 34997786 Get It

BackgroundPreferential publication of studies with positive findings can lead to overestimation of diagnostic test accuracy (i.e. publication bias). Understanding the contribution of the editorial process to publication bias could inform interventions to optimize the evidence guiding clinical decisions.Purpose/HypothesisTo evaluate whether accuracy estimates, abstract conclusion positivity, and completeness of abstract reporting are associated with acceptance to radiology conferences and journals.Study TypeMeta‐research.PopulationAbstracts submitted to radiology conferences (European Society of Gastrointestinal and Abdominal Radiology (ESGAR) and International Society for Magnetic Resonance in Medicine (ISMRM)) from 2008 to 2018 and manuscripts submitted to radiology journals (Radiology, Journal of Magnetic Resonance Imaging [JMRI]) from 2017 to 2018. Primary clinical studies evaluating sensitivity and specificity of a diagnostic imaging test in humans with available editorial decisions were included.AssessmentPrimary variables (Youden's index [YI > 0.8 vs. <0.8], abstract conclusion positivity [positive vs. neutral/negative], number of reported items on the Standards for Reporting of Diagnostic Accuracy Studies [STARD] for Abstract guideline) and confounding variables (prospective vs. retrospective/unreported, sample size, study duration, interobserver agreement assessment, subspecialty, modality) were extracted.Statistical TestsMultivariable logistic regression to obtain adjusted odds ratio (OR) as a measure of the association between the primary variables and acceptance by radiology conferences and journals; 95% confidence intervals (CIs) and P‐values were obtained; the threshold for statistical significance was P < 0.05.ResultsA total of 1000 conference abstracts (500 ESGAR and 500 ISMRM) and 1000 journal manuscripts (505 Radiology and 495 JMRI) were included. Conference abstract acceptance was not significantly associated with YI (adjusted OR = 0.97 for YI > 0.8; CI = 0.70–1.35), conclusion positivity (OR = 1.21 for positive conclusions; CI = 0.75–1.90) or STARD for Abstracts adherence (OR = 0.96 per unit increase in reported items; CI = 0.82–1.18). Manuscripts with positive abstract conclusions were less likely to be accepted by radiology journals (OR = 0.45; CI = 0.24–0.86), while YI (OR = 0.85; CI = 0.56–1.29) and STARD for Abstracts adherence (OR = 1.06; CI = 0.87–1.30) showed no significant association. Positive conclusions were present in 86.7% of submitted conference abstracts and 90.2% of journal manuscripts.Data ConclusionDiagnostic test accuracy studies with positive findings were not preferentially accepted by the evaluated radiology conferences or journals.Evidence Level3Technical EfficacyStage 2.